# Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

> **NCT04167345** · PHASE2 · TERMINATED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 48 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** VX-814
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04167345
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-13
- **Primary completion:** 2020-11-14
- **Final completion:** 2020-11-14
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** at Sponsor's discretion
- **Last updated:** 2022-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167345, "Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04167345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*